Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a ...

The firm said it found its antibody-drug conjugate payload had activity as both a monotherapy and in combination with androgen receptor inhibitors.

The approval follows the CHMP's reversal of a previous decision not to recommend the drug, instead recommending it with certain restrictions.

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...